1 Advanced Biomed Inc. Receivables Turnover Ratio (ADVB), from the third quarter 2026 to the third quarter 2025 current and historic results, rankings and more - CSIMarket

Company Name, Ticker, Industry, else..

Growth Rates

Profitability

Valuation Comparisons

Management Effectiveness

Financial Strength

Efficiency

• Sales per Employee

• Income per Employee

• Inventory Turnover

• Asset Turnover

• Receivables Turnover

Dividend Comparisons

Advanced Biomed Inc. (Nasdaq: ADVB)

Sector • Healthcare Industry • Medical Laboratories

Industry • Medical Laboratories

Sector • Healthcare

Advanced Biomed Accounts Receivables Turnover Ratio from the third quarter 2026 to the third quarter 2025

Quarterly Results, Trends, Rankings, Statistics

According to Advanced Biomed Inc. Balance Sheet, in the third quarter 2026, company has not reported any Accounts receivable.
See Advanced Biomed Inc. Balance Sheet

If we take a look into Healthcare sector Advanced Biomed Inc. achieved the highest receivable turnover ratio. While receivables turnover ratio remained unchanged relative to the previous period at no. .

What is Receivable Turnover Ratio?
What is Advanced Biomed Inc. Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ADVB Receivables Turnover Ratio	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter	(Mar 31 2025) III. Quarter
Y / Y Receivable Change	-	-	-	-	-
Y / Y Revenue Change	-	-	-	-	-
Receivable Turnover Ratio (TTM)	-	-	-	-	-
ADVB's Total Ranking	#	#	#	#	#
Accounts Receivable average collection period days	-	-	-	-	-
Seq. Receivable Change	-	-	-	-	-
Seq. Revenue Change	-	-	-	-	-

Receivable Turnover Company Ranking
Within:	No.
Medical Laboratories Industry	#
Healthcare Sector	#
Overall Market	#

Receivable Turnover Ratio Statistics
High	Average	Low
0	0	0

ADVB Company Profile • Back to ADVB Efficiency Comparisons • Compare ADVB Receivables Turnover Ratio to its Competitors

Financial Statements
Advanced Biomed's Accounts Receivable	$ 0 Millions	Visit ADVB's Balance sheet
Advanced Biomed's Sales TTM	$ 0 Millions	Visit ADVB's Income Statement
Sources of ADVB's Revenues		Visit ADVB's Sales by Geography

Other Accounts Receivable Turnover Ratios
Medical Laboratories Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
ADVB's Receivable Turnover Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
ADVB's Growth Rates	ADVB's Roa	ADVB's Inventory Turnover Ratio	ADVB's Dividend Comparisons
ADVB's Profitability Ratios	ADVB's Roi	ADVB's Asset Turnover Ratio	ADVB's Dividend Growth
ADVB's Valuation Ratios	ADVB's Roe	ADVB's Financial Strength Ratios	ADVB's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector

Receivable Turnover Ratio

Revenues for 12 Months ending Mar 31 2026

Receivable at quarter ending Mar 31 2026

Date modified: 2026-09-04T09:58:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.